2023 World Conference on Lung Cancer (Posters)-P1.21. The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity

P1.21. The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity - PDF(Slides)

Back to course

Pdf Summary

In this study, the role of IGF2BP2, a reader protein, as an oncogenic gene in lung adenocarcinoma (LUAD) was explored. Data from various databases were used to analyze the expression and functional implications of IGF2BP2 in LUAD. It was found that IGF2BP2 expression was significantly upregulated in LUAD and patients with high IGF2BP2 levels had poor overall survival, disease-free survival, progression-free interval, and progression-free survival. IGF2BP2 was found to be present in various lung tissue cell types, particularly macrophages and alveolar cells. It was also extensively expressed in different immune cells, including myeloid dendritic cells and monocytes. IGF2BP2 was positively associated with CD4T cells, CD8T cells, neutrophils, macrophages, and myeloid dendritic cells, while negatively with B cells in LUAD. GSEA analysis revealed that IGF2BP2 influenced the immune microenvironment by affecting various tumor HALLMARK gene sets and biological processes such as fatty metabolism, glycolysis, oxidative phosphorylation, DNA damage repair, and cell cycle regulation. Additionally, RNA editing of IGF2BP2 was associated with the sensitivity of multiple chemotherapeutics. Based on these findings, it was concluded that highly expressed IGF2BP2 predicts worse prognosis and shorter survival time in LUAD. It also plays a significant role in regulating immune cells infiltration level, metabolism pathway, and drug resistance. Therefore, IGF2BP2 may serve as a potential immune therapeutic and drug resistance target in LUAD.

Asset Subtitle

Xuequan Wang

Meta Tag

Speaker Xuequan Wang

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

IGF2BP2

oncogenic gene

lung adenocarcinoma

LUAD

expression

overall survival

immune cells

tumor microenvironment

drug resistance

immune therapeutic